A separate report from IQVIA on the clinical trial ecosystem in Europe, published in 2024, underscores Denmark’s position as one of Europe’s strongest ecosystems for clinical trials. The report concludes that this, amongst others, is based on Denmark taking proactive, cross-stakeholder actions to ensure the country is an attractive location for clinical trials.
The new Danish life science strategy, published at the end of 2024,there is also a great focus on strengthening the conditions for conducting clinical trials in Denmark. One key initiative is the establishment of a fourth scientific ethical committee that will focus on procession applications for phase I trial within 14 days. The aim in the life science strategy is for Denmark to be among the countries in Europa that performs the most clinical trials per capita in the years leading up to 2030.
Denmark’s continuous investment in clinical research, coupled with strong public engagement, ensures that the country remains at the forefront of global medical innovation - offering benefits not only to patients but to the entire healthcare ecosystem.
